A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALXN1830 Administered Subcutaneously in Adult Patients With Generalized Myasthenia Gravis
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Orilanolimab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Alexion AstraZeneca Rare Disease
Most Recent Events
- 15 Nov 2021 Planned End Date changed from 1 Jan 2024 to 31 Jan 2024.
- 15 Nov 2021 Planned primary completion date changed from 1 Jan 2023 to 31 Jan 2023.
- 15 Nov 2021 Planned initiation date changed to 1 Jan 2022.